Earlier challenges will curb patent settlements

01/31/2013 | Politico (Washington, D.C.)

Allowing an opposition proceeding sooner could eliminate low-quality drug patents early in an inexpensive and relatively fast proceeding, writes Alfred Engelberg, former patent counsel of the Generic Pharmaceutical Association. The growth of the generic drug industry has rendered many of the provisions of 1984's Hatch-Waxman Act unnecessary, and change is needed to end a system of patent settlements and low-quality patents that stifle competition, Engelberg writes.

View Full Article in:

Politico (Washington, D.C.)

Published in Brief: